Emergent BioSolutions (EBS) EBITDA Margin Growth (1y) (2012 - 2026)
Emergent BioSolutions (EBS) EBITDA Margin Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 304.00 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -157.00 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5,330.00 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -650.00 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 8,630.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1,962.00 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 111.00 |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | -1,573.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,573.00 |
| Dec 31, 2025 | -1,388.00 |
| Sep 30, 2025 | 1,115.00 |
| Jun 30, 2025 | 40,814.00 |
| Mar 31, 2025 | 921.00 |
| Dec 31, 2024 | 1,096.00 |
| Sep 30, 2024 | 11,145.00 |
| Jun 30, 2024 | -32,032.00 |
| Mar 31, 2024 | 10,308.00 |
| Dec 31, 2023 | 91.00 |
| Sep 30, 2023 | -7,062.00 |
| Jun 30, 2023 | -5,523.00 |
| Mar 31, 2023 | -9,210.00 |
| Dec 31, 2022 | -5,588.00 |
| Sep 30, 2022 | -327.00 |
| Jun 30, 2022 | -3,333.00 |
| Mar 31, 2022 | -2,219.00 |
| Dec 31, 2021 | -514.00 |
| Sep 30, 2021 | -3,153.00 |
| Jun 30, 2021 | -3,004.00 |